



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Geoffrey HALE et al.

Serial Number: 09/613,824/3

923

Group Art Unit: 1646

Filed: July 11, 2000

Examiner: Not Assigned

For: CDW52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. 1.97(b)

Assistant Commissioner
for Patents
Washington, D.C. 20231

October 18, 2000

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the last of (1) issuance of a first official action on the merits and (2) expiration of the three month period following filing of the above-captioned application.

GP 1646
#5 R12-21-0

PATENT
RECEIVED

OCT 20 2000

TECH CENTER 1600/2900

RECEIVED

DEC 15 2000

TECH CENTER 1600/2900

TECH CENTER 2700

OCT 25 2000

RECEIVED

CONTINUATION APPLICATION OF S.N. 09/504,046
INFORMATION DISCLOSURE STATEMENT

RECEIVED
PATENT

DEC 23 2000

TECH CENTER 1600/2900

These documents are of record in parent application Serial No.

08/244,316, filed June 22, 1994, now U.S. Patent No. 6,120,766

RECEIVED

which is a 371 of PCT/GB92/02252.

DEC 15 2000

TECH CENTER 1600/2900

Documents FA, FB and DA were cited in the International Search Report for this PCT application, PCT/GB92/02252. A copy of the International Search Report is enclosed herewith.

Documents FA and DA were also cited in an Office Action dated December 7, 1995. Documents FA, DB and DC were cited in an Office Action dated September 9, 1996. Copies of Notice of References Cited PTO-892 attached to each Office Action (paper Nos. 7 and 13) are enclosed.

Documents DD and DE are described in the specification of the present application, lines 31-33 on page 3, and lines 4 and 5 on page 4, respectively, and were discussed and submitted with an Amendment filed on March 10, 1997, in response to the Office Action dated September 9, 1996. Copies of the Amendment and initialed

CONTINUATION APPLICATION OF S.N. 09/504,046
INFORMATION DISCLOSURE STATEMENT

PATENT

PTO-1449 are enclosed.

Documents UA to UC were cited in an Office Action dated March 4, 1998. A copy of PTO-892 attached to the Office Action (paper No. 17) is enclosed.

Document DF was discussed and submitted with an Amendment under 37 C.F.R. §1.116 to respond to an Office Action dated April 15, 1997, filed in the USPTO on February 17, 1998. A copy of the Amendment is also enclosed. Document DG was discussed and submitted with an Amendment filed January 19, 2000, in response to an Office Action dated July 20, 1999. A copy of the Amendment is enclosed.

No concise explanation of the relevance of documents UA to UC, FA, FB, DA, DB and DD to DG is believed to be required under 37 C.F.R. §1.98 because the documents are in English. Document DC is not in English, but was cited by the Examiner in an Office Action dated September 6, 1996.

CONTINUATION APPLICATION OF S.N. 09/504,046
INFORMATION DISCLOSURE STATEMENT

PATENT

The Commissioner is authorized to charge our Deposit Account
No. 111833 for any fee which is deemed by the Patent and Trademark
Office to be required to effect consideration of this statement.

Respectfully submitted,

KUBOVCIK & KUBOVCIK



Keiko Tanaka Kubovcik
Reg. No. 40,408

Atty. Case No.: ELK-002-001
The Farragut Building
Suite 710
900 17th Street, N.W.
Washington, D.C. 20006
Tel: (202) 887-9023
Fax: (202) 887-9093
KTK/spb

Attachments: PTO-1449
International Search Report
Copy of PTO-892 attached to Office Actions (paper
Nos. 7, 13 and 17)
Copy of Amendment filed March 10, 1997 and
initialed PTO-1449
Copy of Amendment Under 37 C.F.R. §1.116 filed
February 17, 1998
Copy of Amendment filed January 19, 1999